Pulmonary position cryopreserved homografts: Durability in pediatric Ross and non-Ross patients

Elif Seda Selamet Tierney, MD,* Welton M. Gersony, MD, Karen Altmann, MD, David E. Solowiejczyk, MD, Laura M. Bevilacqua, MD,* Chava Khan, Ehud Krongrad, MD, Ralph S. Mosca, MD, Jan M. Quaegebeur, MD, PhD, and Howard D. Apfel, MD

Objective: The purpose of this study was to evaluate the outcome and risk factors for implant failure in pediatric patients who underwent pulmonary position homograft placement for right ventricular outflow tract obstruction compared with conduit placement as a component of the Ross operation. Actuarial 5-year survivals for cryopreserved right ventricle–to–pulmonary artery homografts range from 55% to 94% at all ages. It is not known whether there is a difference in homograft durability when utilized for right ventricular outflow tract obstruction or as part of the Ross operation.

Methods: The records of all pediatric patients receiving a right ventricle–to–pulmonary artery homograft from July 1989 through October 2003 were reviewed. Ninety-eight consecutive patients were studied (26 Ross, 72 non-Ross). In addition to Ross versus non-Ross comparisons, other potential risk factors for homograft failure analyzed included age at operation, follow-up time, type of surgery, and homograft type and size.

Results: Ross and non-Ross patients were comparable in age at the time of the operation and follow-up time. Homograft failure rates were 12% and 51% for Ross and non-Ross patients, respectively. Freedom from reintervention was 93% in the Ross and 66% in the non-Ross group at 5 years ($P = .019$). On multivariate analysis, non-Ross operation and age less than 2 years were significant predictors of homograft failure.

Conclusions: 1. Pediatric patients undergoing the Ross operation have longer homograft survival than pediatric patients treated for right ventricular outflow tract obstruction, independent of age. 2. Homografts placed in patients less than 2 years of age have shorter homograft survival.

In 1966, Ross and Somerville reported the first use of an aortic homograft to establish right ventricle–to–pulmonary artery continuity in a patient with tetralogy of Fallot and pulmonary atresia. Since that time, pulmonary position homografts have been used in a variety of right-sided congenital heart lesions. Actuarial 5-year homograft survivals for cryopreserved homografts are reported to range between 55% and 94%, with the shortest durability noted in patients less than 2 years of age.

Pulmonary position homografts also are used to replace pulmonary autografts explanted to repair left-sided outflow disease (the Ross operation). Several factors may be likely to favor increased pulmonary conduit durability in Ross patients compared with those with right ventricular outflow tract obstruction, including later age at operation (allowing for larger homografts), more normal pulmonary artery architecture, absence of severe right ventricular hypertrophy, and more natural positioning of the homograft. However, this concept has not been systematically
Ninety-eight patients were included in the study (Table 1).

### Results

The hospital records of all patients less than 10 years of age receiving primary cryopreserved right ventricle-to-pulmonary artery homografts at Children’s Hospital of New York from July 1989 through October 2003 were reviewed. Cryopreserved homografts were obtained from Cryolife, Inc (Kennesaw, Ga). All homografts were used in the Ross group (73% vs 40%, 16.5 ± 4.6 vs 18.1 ± 4.3, P = .02), and more pulmonary type homografts were used in the Ross group (73% vs 40%, P = .01; Table 1). Figure 1 demonstrates the age distribution, which was not statistically different between the Ross and non-Ross groups. The homograft size was greater in the Ross group (19.2 ± 3.9 vs 16.5 ± 4.8 mm, P = .02), and more pulmonary type homografts were used in the Ross group (73% vs 40%, P = .01; Table 1).

The non-Ross group consisted of 3 major groups (Table 1): patients undergoing homograft placement as a component of the Rastelli procedure (n = 23), variants of tetralogy of Fallot (n = 37), or truncus arteriosus (n = 11) repair. Patients with truncus arteriosus were the youngest in this group (0.09 ± 0.3 years), and these patients had smaller homografts placed (13.0 ± 5.5 mm).

The characteristics of patients with homograft failure are listed in Table 2. The overall homograft failure rate was 41%. Three (12%) patients in the Ross group had failure of left-sided heart disease. Seventy-two patients with right ventricular outflow tract obstruction (non-Ross group) were studied.

The mean follow-up time was 5.1 years (range, 1.25 months-14.7 years) for all patients (Table 1). The 2 groups were comparable in age at the time of the operation (3.4 vs 2.1 years, P = .2) and follow-up time (5.2 ± 4 vs 4.8 ± 3.8 years, P = .7; Table 1). Figure 1 demonstrates the age distribution, which was not statistically different between the Ross and non-Ross groups. The homograft size was greater in the Ross group (19.2 ± 3.9 vs 16.5 ± 4.8 mm, P = .02), and more pulmonary type homografts were used in the Ross group (73% vs 40%, P = .01; Table 1).

The non-Ross group consisted of 3 major groups (Table 1): patients undergoing homograft placement as a component of the Rastelli procedure (n = 23), variants of tetralogy of Fallot (n = 37), or truncus arteriosus (n = 11) repair. Patients with truncus arteriosus were the youngest in this group (0.09 ± 0.3 years), and these patients had smaller homografts placed (13.0 ± 5.5 mm).

The characteristics of patients with homograft failure are listed in Table 2. The overall homograft failure rate was 41%. Three (12%) patients in the Ross group had failure of left-sided heart disease. Seventy-two patients with right ventricular outflow tract obstruction (non-Ross group) were studied.

The mean follow-up time was 5.1 years (range, 1.25 months-14.7 years) for all patients (Table 1). The 2 groups were comparable in age at the time of the operation (3.4 vs 2.1 years, P = .2) and follow-up time (5.2 ± 4 vs 4.8 ± 3.8 years, P = .7; Table 1). Figure 1 demonstrates the age distribution, which was not statistically different between the Ross and non-Ross groups. The homograft size was greater in the Ross group (19.2 ± 3.9 vs 16.5 ± 4.8 mm, P = .02), and more pulmonary type homografts were used in the Ross group (73% vs 40%, P = .01; Table 1).

The non-Ross group consisted of 3 major groups (Table 1): patients undergoing homograft placement as a component of the Rastelli procedure (n = 23), variants of tetralogy of Fallot (n = 37), or truncus arteriosus (n = 11) repair. Patients with truncus arteriosus were the youngest in this group (0.09 ± 0.3 years), and these patients had smaller homografts placed (13.0 ± 5.5 mm).

The characteristics of patients with homograft failure are listed in Table 2. The overall homograft failure rate was 41%. Three (12%) patients in the Ross group had failure of left-sided heart disease. Seventy-two patients with right ventricular outflow tract obstruction (non-Ross group) were studied.

The mean follow-up time was 5.1 years (range, 1.25 months-14.7 years) for all patients (Table 1). The 2 groups were comparable in age at the time of the operation (3.4 vs 2.1 years, P = .2) and follow-up time (5.2 ± 4 vs 4.8 ± 3.8 years, P = .7; Table 1). Figure 1 demonstrates the age distribution, which was not statistically different between the Ross and non-Ross groups. The homograft size was greater in the Ross group (19.2 ± 3.9 vs 16.5 ± 4.8 mm, P = .02), and more pulmonary type homografts were used in the Ross group (73% vs 40%, P = .01; Table 1).

The non-Ross group consisted of 3 major groups (Table 1): patients undergoing homograft placement as a component of the Rastelli procedure (n = 23), variants of tetralogy of Fallot (n = 37), or truncus arteriosus (n = 11) repair. Patients with truncus arteriosus were the youngest in this group (0.09 ± 0.3 years), and these patients had smaller homografts placed (13.0 ± 5.5 mm).

The characteristics of patients with homograft failure are listed in Table 2. The overall homograft failure rate was 41%. Three (12%) patients in the Ross group had failure of left-sided heart disease. Seventy-two patients with right ventricular outflow tract obstruction (non-Ross group) were studied.

The mean follow-up time was 5.1 years (range, 1.25 months-14.7 years) for all patients (Table 1). The 2 groups were comparable in age at the time of the operation (3.4 vs 2.1 years, P = .2) and follow-up time (5.2 ± 4 vs 4.8 ± 3.8 years, P = .7; Table 1). Figure 1 demonstrates the age distribution, which was not statistically different between the Ross and non-Ross groups. The homograft size was greater in the Ross group (19.2 ± 3.9 vs 16.5 ± 4.8 mm, P = .02), and more pulmonary type homografts were used in the Ross group (73% vs 40%, P = .01; Table 1).

The non-Ross group consisted of 3 major groups (Table 1): patients undergoing homograft placement as a component of the Rastelli procedure (n = 23), variants of tetralogy of Fallot (n = 37), or truncus arteriosus (n = 11) repair. Patients with truncus arteriosus were the youngest in this group (0.09 ± 0.3 years), and these patients had smaller homografts placed (13.0 ± 5.5 mm).

The characteristics of patients with homograft failure are listed in Table 2. The overall homograft failure rate was 41%. Three (12%) patients in the Ross group had failure of

---

### Table 1. Patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>Ross (n = 26)</th>
<th>Non-Ross (n = 72)</th>
<th>P value*</th>
<th>Total (n = 98)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at operation (y)</td>
<td>3.4 ± 3.4</td>
<td>2.1 ± 0.3</td>
<td></td>
<td>2.3 ± 2.5</td>
</tr>
<tr>
<td>Homograft size (mm)</td>
<td>19.2 ± 3.9</td>
<td>16.5 ± 4.8</td>
<td></td>
<td>16.5 ± 4.6</td>
</tr>
<tr>
<td>Pulmonary type homograft</td>
<td>19 (73%)</td>
<td>29 (40%)</td>
<td></td>
<td>16 (43%)</td>
</tr>
<tr>
<td>Follow-up time (y)</td>
<td>5.2 ± 4.0</td>
<td>4.8 ± 3.8</td>
<td></td>
<td>5.5 ± 4.0</td>
</tr>
</tbody>
</table>

Values are presented as means ± SD where shown. TOF, Tetralogy of Fallot variant; PS, pulmonary stenosis. *Ross versus non-Ross.
TABLE 2. Homograft failure

<table>
<thead>
<tr>
<th></th>
<th>Ross (n = 3)</th>
<th>Non-Ross (n = 37)</th>
<th>TOF (n = 20)</th>
<th>Rastelli (n = 9)</th>
<th>Truncus (n = 7)</th>
<th>PS (n = 1)</th>
<th>Total (n = 40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Homograft failure (%)</td>
<td>12%</td>
<td>51%</td>
<td>54%</td>
<td>39%</td>
<td>64%</td>
<td>1/1</td>
<td>41%</td>
</tr>
<tr>
<td>Age at operation (y)</td>
<td>4.1 ± 4.8</td>
<td>2.0 ± 2.3</td>
<td>2.1 ± 2.6</td>
<td>1.9 ± 1.8</td>
<td>0.14 ± 0.4</td>
<td>3.1</td>
<td>2.2 ± 2.5</td>
</tr>
<tr>
<td>Homograft size (mm)</td>
<td>20.3 ± 4.6</td>
<td>15.6 ± 5.4</td>
<td>16 ± 5.5</td>
<td>17.3 ± 5.2</td>
<td>12.0 ± 4.8</td>
<td>18.0</td>
<td>16.0 ± 5.5</td>
</tr>
<tr>
<td>Pulmonary type homograft</td>
<td>3 (100%)</td>
<td>15 (41%)</td>
<td>9 (45%)</td>
<td>2 (22%)</td>
<td>3 (43%)</td>
<td>1/1</td>
<td>18 (45%)</td>
</tr>
<tr>
<td>Failure time from operation (mo)</td>
<td>83.0 ± 38</td>
<td>53.2 ± 47</td>
<td>52.4 ± 50</td>
<td>57.1 ± 50</td>
<td>50.0 ± 46</td>
<td>56</td>
<td>55.4 ± 47</td>
</tr>
</tbody>
</table>

Values are presented as means ± SD where shown. TOF, Tetralogy of Fallot variant; PS, pulmonary stenosis.

the homograft, whereas 37 (51%) in the non-Ross group had failure of the homograft. Patients in the Ross group experienced failure at a mean of 83.0 ± 38 months after the operation, whereas those in the non-Ross group experienced failure at a mean of 53.2 ± 47 months after the operation (Table 2). At the time of homograft failure, the maximum instantaneous homograft gradient, as determined by Doppler echocardiography, was 90.7 ± 10 mm Hg in the Ross group and 67.9 ± 29 mm Hg in the non-Ross group (P = .2). Intervention was required in 8 (8%, all in the non-Ross group) patients within 6 months, in 18 (18%, all in the non-Ross group) patients within 3 years, and in 40 (41%, 37 in the non-Ross group and 3 in the Ross group) patients within 6 years. There was no significant difference in re-reintervention rates among the different non-Ross procedures.

Homograft survival at 5 years was 93% in the Ross group (median follow-up time, 52.9 months) and 66% in the non-Ross group (median follow-up time, 61.3 months), as shown in the actuarial graph (P = .019, Figure 2).

On univariate analysis, non-Ross operation, age less than 2 years at the time of the operation, smaller homograft size, and an aortic-type homograft were significant risk factors for homograft failure; on multivariate analysis, non-Ross operation and age less than 2 years independently remained significant to predict homograft failure (Table 3).

There were 9 infants in the Ross group (4.1 ± 3.9 months; median age, 4 months), of whom only 1 (11%) patient experienced homograft failure during the follow-up period (8 months old at the time of the operation, homograft failure 121 months after the operation). Of 27 infants in the non-Ross group (2.6 ± 3.7 months; median age, 1 month), 15 (55%) experienced homograft failure within an average of 56.7 ± 44 months after the operation.

Discussion

Over the past 15 years, the Ross operation has become the operation of choice for children and young adults with left-sided outflow tract disease. The increased popularity of this procedure is largely due to the efficacy of the Ross operation in relieving left ventricular outflow tract obstruction in children, the pulmonary autograft’s potential for growth, and greater experience with the technical demands of the operation. In addition, the relatively low risk for later right ventricle–to–pulmonary artery conduit replacement has generated less concern over the placing of a second valve at risk (by replacement of the normal native pulmonary artery with a valved conduit) and has contributed to the preference for this procedure. The latter factor appears to stem from a general sense that pulmonary circulation conduits fare better in Ross patients than in others.

Although the idea that Ross patients have greater right ventricular conduit durability has been anecdotally noted in several reports,2 6,7 it has never been formally documented. The most likely reason for this is that conduit outcome reviews have predominantly studied older patients in the Ross group and younger ones in the non-Ross group. Since conduits generally last longer in older patients, irrespective of diagnosis or surgical procedure,8 there is a bias favoring Ross patients on initial univariate analysis. This is usually confirmed on multivariate analysis, in which the Ross procedure variable is lost, whereas age at operation and conduit size remain significant predictors. For example, Niwaya and colleagues2 reviewed the results of 331 (259 Ross and 72
non-Ross) patients who underwent right ventricle–to–pulmonary artery conduit placement for various indications (median age, 14 years; 38 patients were less than 3 years old) and reported that young age and non-Ross operation were risk factors for failure. However, on multivariate analysis, the use of an aortic homograft, younger age, and later year of operation were the only risk factors for homograft dysfunction. With reasoning similar to that discussed above, Forbess and coworkers’ use of age of the patient to stratify the implant population into younger and older patient groups. However, a final comparison of the groups was not possible because of insufficient patient numbers, with only 9 patients in the Ross group being less than 10 years of age.

The present study was specifically designed to analyze right ventricular conduit outcomes in Ross and non-Ross group patients of comparable age and conduit size. In order to best assess for differences in conduit durability, we focused on the patient population known to be most susceptible to conduit failure, those less than 10 years of age. On multivariate analysis, the non-Ross procedure and age less than 2 years were shown to be significant independent predictors of worse outcome.

A common explanation offered for the superior conduit durability in Ross patients has emphasized the placement of the homograft in the orthotopic pulmonary position in the right ventricular outflow tract. One might also speculate that sternal compression of the more anteriorly placed conduits could play a role in the earlier failure of non-Ross conduits. A study by Carr-White and colleagues in 2001 suggested that the predominant mechanism of homograft stenosis was a poorly understood inflammatory reaction. This suggestion was based on their noting of early onset of stenosis, rapid clinical progression, as well as magnetic resonance images and histology of explanted homografts. The cause of the inflammation was unclear; however, early postoperative stretching and lengthening of the homograft causing release of tissue factors was one possibility suggested. It is possible to speculate that the extent of that phenomenon might relate to the degree of peripheral vascular distortion present. To further tease out that possibility, one would need to analyze in detail the degree of architectural abnormality in the group of patients with right-sided outflow tract disease and search for an association with conduit failure. The current retrospective nature of this study and limited patient number prevented that analysis from being attempted here. Such information might be useful, for example, in deciding to forego conduit placement in patients considered at risk for early conduit failure and instead consider more technically challenging approaches to achieving direct right ventricle–to–pulmonary artery continuity.

We thank Dr Robert Sciacca for the statistical analysis of this project.

References


TABLE 3. Risk factors for homograft failure

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hazard ratio (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>Non-Ross</td>
<td>4.08 (1.26-13.24)</td>
<td>.019</td>
</tr>
<tr>
<td>Age &lt;2 y</td>
<td>2.26 (1.18-4.35)</td>
<td>.015</td>
</tr>
<tr>
<td>Aortic homograft</td>
<td>2.30 (1.15-4.60)</td>
<td>.018</td>
</tr>
<tr>
<td>Smaller homograft size</td>
<td>2.72 (1.44-5.16)</td>
<td>.002</td>
</tr>
</tbody>
</table>

CI, Confidence interval.


